We all witnessed how the left has been pushing away the idea of Ivermectin to be a Covid therapeutic until this vintage medicine comes and saves the day.
The drug is known as Disulfiram was originally intended to treat alcoholism but after researchers studied the drugs’ proper functioning, Disulfiram works by preventing neutrophil extracellular traps from trapping water in the lungs—which leads to COPD like complications and could potentially lead to blood clots.
The Epoch Times gave us some insight into the research:
Researchers dosed the mice with disulfiram a day before and three hours after infecting them with the virus that causes COVID-19. Some 95 percent of those mice survived, compared to 40 percent not treated with the drug.
The new study and a previous one that linked disulfiram with the reduced NET formation and improved survival “suggest that disulfiram could be useful in the management of pathologies involving NETs, including lung injuries, sepsis, thrombosis, and cancer,” the researchers said in the paper, which was published by The Journal of Clinical Investigation on Feb. 8.
Happy to share that we found FDA-approved Disulfiram to be an effective way to block NET-formation in vivo in two independent preclinical models of lung injury (TRALI and SARS-CoV-2 infection), leading to increased survival and reduced lung damage. https://t.co/fSOccIMWEC
— Jose M. Adrover (@niseto) February 8, 2022
Disulfiram (FDA-approved) prevents immune system from producing toxic webs known as neutrophil extracellular traps (NETs) and could protect lungs during covid infection.
Clinical trials in symptomatic patients are underwayhttps://t.co/IIlAptlieG— Laurence Bettle (@LaurenceBettle) February 10, 2022
This may be a new shed of hope for us who are leery of these COVID-19 vaccines that have been putting us in a very awkward situation.
The Cold Spring Harbor Laboratory led the research into the drug as a Covid-19 treatment:
Disulfiram is the first FDA-approved drug that can block NET formation. In this study, Egeblad’s team dissects the drug’s ability to block NETs and change immune signaling in a way that may be beneficial for treating severe COVID-19. Their results are reported in JCI Insight.
Clinical trials investigating disulfiram’s use in patients with symptomatic COVID-19 are underway, and while CSHL scientists are not involved in those studies, Egeblad says, “Our findings provide a reason to hope that disulfiram may be a useful treatment.
Sources: We Love Trump, The Epoch Times, The Cold Spring Harbor Laboratory